As an integral step in Redwood Pharma’s activities in preparation for the clinical trial of RP101 in patients with dry eye disease, CARBOGEN AMCIS has been awarded the contract for production of RP101, the company’s new drug candidate according to Good Manufacturing Practice (GMP). CARBOGEN AMCIS has capabilities within development and production of pharmaceuticals, as well as global manufacturing facilities. The firm is based in Switzerland. CARBOGEN AMCIS’ integrated services offer its customers access to innovative, up-to-date and safe pharmaceutical development solutions that allow customers to optimize their available resources. For more information regarding CARBOGEN AMCIS, visit www.carbogen-amcis.com Martin Vidaeus, CEO of Redwood Pharma, comments, ” CARBOGEN AMCIS is a contract manufacturing organization with many years’ experience and with a broad range of technical capabilities for our class of product. The firm will now assist Redwood Pharma with manufacturing of RP101, and with this agreement, we strengthen our development expertise and ensure a stable path towards the clinical trial.”